Entia Biosciences (ERGO) 10-K 19 May 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	May 19, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Entia Biosciences, Inc.
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		33,660,947
Entity Public Float			$ 1,223,982
Amendment Flag	false
Entity Central Index Key	1,408,299
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current Assets:
Cash	$ 76,050	$ 24,133
Accounts receivable, net	7,973	7,098
Inventory, net	69,759	40,323
Prepaid expenses	80,565	56,782
Total Current Assets	234,347	128,336
Property and Equipment, net	18,285	32,686
Patents and Licenses, net	186,509	232,584
Long-Term Inventory	0	55,000
Total Assets	439,141	448,606
Current Liabilities:
Accounts payable and accrued expenses	1,359,702	960,557
Line of credit	59,945	58,195
Short-term notes payable, related-party	10,000	0
Short-term convertible notes payable, net of discount	605,436	181,981
Short-term convertible notes payable, net of discount, related party	8,322	0
Notes payable	62,219	39,061
Total Current Liabilities	2,105,624	1,239,794
Long Term Liabilities:
Convertible notes payable, net of discount and current portion-related party	24,028	0
Convertible notes payable, net of discount	276,050	0
Total Long Term Liabilities	300,078	0
Total Liabilities	2,405,702	1,239,794
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value, 5,000,000 shares authorized, Series A preferred stock, 350,000 shares designated, 188,563 and 191,307 shares issued and outstanding, respectively, aggregate liquidation value of $942,815 and $956,535 respectively	188	191
Common stock, $0.001 par value, 150,000,000 shares authorized, 28,149,777 and 28,107,337 shares issued and outstanding, respectively	28,150	28,108
Additional paid-in capital	12,486,728	12,309,450
Deferred compensation	(8,853)	(51,945)
Accumulated deficit	(14,472,774)	(13,076,992)
Total Stockholders' Equity (Deficit)	(1,966,561)	(791,188)
Total Liabilities and Stockholders' Equity (Deficit)	$ 439,141	$ 448,606

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	28,149,777	28,107,337
Common stock, shares outstanding	28,149,777	28,107,337
Series A Preferred Stock [Member]
Preferred stock, shares authorized	350,000	350,000
Preferred stock, shares issued	188,563	191,307
Preferred stock, shares outstanding	188,563	191,307
Preferred stock, aggregate liquidation value (in Dollars)	$ 942,815	$ 956,535

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
REVENUES	$ 265,466	$ 346,910
COST OF GOODS SOLD	91,499	131,007
GROSS PROFIT	173,967	215,903
OPERATING EXPENSES
Advertising and promotion	90,143	127,127
Professional fees	222,203	231,125
Consulting fees	68,965	344,112
Impairment of licenses	49,895	110,000
Loss on litigation	93,074	0
General and administrative	960,035	1,429,495
Total Operating Expenses	1,484,315	2,241,859
LOSS FROM OPERATIONS	(1,310,348)	(2,025,956)
OTHER INCOME (EXPENSES)
Interest expense	(83,512)	(149,284)
Other expense	(6,630)	(35,895)
Loss on settlement/conversion of notes payable	0	(32,500)
Loss on write-off of debt discount	0	(23,321)
Gain on extinguishment of debt	4,708	0
Gain on settlement of accounts payable	0	6,906
NET LOSS	$ (1,395,782)	$ (2,260,050)
NET LOSS PER COMMON SHARE - BASIC AND DILUTED: (in Dollars per share)	$ (0.05)	$ (0.09)
Weighted common shares outstanding - basic and diluted (in Shares)	28,136,527	24,289,381

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Conversion of Convertible Debt [Member]Common Stock [Member]	Conversion of Convertible Debt [Member]Additional Paid-in Capital [Member]	Conversion of Convertible Debt [Member]	Conversion of Preferred Stock [Member]Preferred Stock [Member]	Conversion of Preferred Stock [Member]Common Stock [Member]	Conversion of Preferred Stock [Member]Additional Paid-in Capital [Member]	Preferred Stock [Member]	Common Stock [Member]Conversion of Accounts Payable [Member]	Common Stock [Member]Conversion of Warrants [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Warrants Issued for Convertible Notes [Member]	Additional Paid-in Capital [Member]Conversion of Accounts Payable [Member]	Additional Paid-in Capital [Member]Conversion of Warrants [Member]	Additional Paid-in Capital [Member]Warrants Issued for Services [Member]	Additional Paid-in Capital [Member]	Deferred Compensation, Share-based Payments [Member]Warrants Issued for Services [Member]	Deferred Compensation, Share-based Payments [Member]	Retained Earnings [Member]	Warrants Issued for Convertible Notes [Member]	Conversion of Accounts Payable [Member]	Total
Balance at Dec. 31, 2014							$ 201			$ 15,514					$ 10,771,035		$ (86,344)	$ (10,816,942)			$ (116,536)
Balance (in Shares) at Dec. 31, 2014							200,807			15,512,927
Issuance of warrants											$ 10,000			$ 67,889	7,891	$ (67,889)			$ 10,000		7,891
Amortization of deferred compensation																	102,288				102,288
Deferral of offering fees															(26,700)						(26,700)
Net loss																		(2,260,050)			(2,260,050)
Issuance of common stock for cash										$ 5,348					554,825						560,173
Issuance of common stock for cash (in Shares)										5,347,901
Issuance of common stock for conversion of securities	$ 3,069	$ 318,632	$ 321,701	$ (10)	$ 95	$ (85)		$ 554	$ 2,051			$ 130,054	$ (2,051)							$ 130,608
Issuance of common stock for conversion of securities (in Shares)	3,068,882			(9,500)	95,000			554,521	2,050,923
Stock compensation										$ 1,550					555,394						556,944
Stock compensation (in Shares)										1,550,000
Cancellation of shares issued to executives as compensation										$ (1,000)					(199,000)						(200,000)
Cancellation of shares issued to executives as compensation (in Shares)										(1,000,000)
Issuance of common stock for services										$ 927					121,566						122,493
Issuance of common stock for services (in Shares)										927,183
Balance at Dec. 31, 2015							$ 191			$ 28,108					12,309,450		(51,945)	(13,076,992)			(791,188)
Balance (in Shares) at Dec. 31, 2015							191,307			28,107,337
Issuance of warrants															110,393						110,393
Amortization of deferred compensation																	43,092				43,092
Net loss																		(1,395,782)			(1,395,782)
Issuance of common stock for conversion of securities							$ (3)			$ 27					(24)
Issuance of common stock for conversion of securities (in Shares)							(2,744)			27,440
Stock compensation															57,774						57,774
Issuance of common stock for services										$ 15					9,135						9,150
Issuance of common stock for services (in Shares)										15,000
Balance at Dec. 31, 2016							$ 188			$ 28,150					$ 12,486,728		$ (8,853)	$ (14,472,774)			$ (1,966,561)
Balance (in Shares) at Dec. 31, 2016							188,563			28,149,777

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS USED IN OPERATING ACTIVITIES:
Net loss	$ (1,395,782)	$ (2,260,050)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation/amortization	17,697	31,996
Gain on settlement of accounts payable	0	(6,906)
Impairment of licenses	49,895	110,000
Gain on extinguishment of debt	(4,708)	0
Loss on write-off of debt discount	0	23,321
Amortization of discount on convertible notes	25,514	113,937
Loss on conversion of notes payable	0	32,500
Stock-based compensation	110,013	589,616
Changes in operating assets and liabilities:
Accounts receivable	(875)	236,684
Inventory	25,564	53
Prepaid expenses	44,643	38,507
Accounts payable and accrued expenses	412,941	553,777
NET CASH USED IN OPERATING ACTIVITIES	(715,098)	(536,565)
CASH FLOWS USED IN INVESTING ACTIVITIES:
Purchase of property and equipment	0	(8,051)
Acquisition of patents	(7,117)	(13,235)
NET CASH USED IN INVESTING ACTIVITIES	(7,117)	(21,286)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	0	560,173
Proceeds from convertible notes payable and notes payable	829,400	100,000
Payment on convertible notes payable and notes payable	(55,268)	0
Payment on notes payable	0	(177,651)
NET CASH PROVIDED BY FINANCING ACTIVITIES	774,132	482,522
NET CHANGE IN CASH	51,917	(75,329)
Cash at beginning of period	24,133	99,462
Cash at end of period	76,050	24,133
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	6,749	37,834
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES:
Stock issued for accounts payable	0	130,608
Common stock issued for services	9,150	122,493
Warrants issued in connection with convertible notes payable	110,393	10,000
Covnersion of Convertible Notes Payable and Acrrued Interest [Member]
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES:
Conversion of convertible notes payable, accounts payable and accrued interest to preferred and common stock	$ 0	$ 321,707

NOTE 1 - BUSINESS

NOTE 1 - BUSINESS	12 Months Ended
	Dec. 31, 2016
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 – BUSINESS We engage in the development, production and distribution of dietary supplements, nutraceuticals and medical foods products, principally in the United States of America. We are also engaged in the discovery, scientific evaluation and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics and other products developed and sold by Entia and by third parties. We have a history of incurring net losses and net operating cash flow deficits. At December 31, 2016, we had cash and cash equivalents of $76,050. These conditions raise substantial doubt about our ability to continue as a going concern. Based on our cash on hand, planned financings, and results from future operations, we believe that we will have sufficient funds to continue operations through 2017. In order for us to continue as a going concern beyond this point and ultimately to achieve profitability, we will likely be required to obtain capital from external sources, and/or increase revenues and/or reduce operating costs. The issuance of equity securities will cause dilution to our shareholders. If external sources of financing are not available or are inadequate to fund our operations, we may be required to reduce operating costs including personnel costs, which could jeopardize our future strategic initiatives and business plans. The accompanying consolidated financial statements have been prepared assuming the Company continues as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.

NOTE 2 - SUMMARY OF SIGNIFICANT

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation and principles of consolidation The accompanying consolidated financial statements and related notes have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Material intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of Entia and Total Nutraceutical Solutions, a wholly-owned subsidiary, as of December 31, 2016 and 2015. Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents. Accounts receivable Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses based on specific identification of accounts in our existing accounts receivable. Outstanding account balances are reviewed individually for collectibility. We determine the allowance based on historical write-off experience, customer specific facts and economic conditions. Bad debt expense is included in general and administrative expenses, if any. We generally consider accounts greater than 30 days old to be past due. Account balances are charged off against allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts was $5,736 at December 31, 2016 and 2015. Inventory Inventory consists of finished goods and raw materials to be used in the production of our dietary supplement products, is stated at the lower of cost or market using the average cost method. We regularly review our inventory on hand and, when necessary, record a provision for excess or obsolete inventory. The portion of inventory that is not expected to be used in production of our products for more than 12 months is a long-term asset. Property and equipment Property and equipment are recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statement of operations. Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets: Office equipment 3 years Production equipment 5 to 7 years Leasehold improvements Lesser of lease term or useful life of improvement Patents Patents, once issued or purchased, are amortized using the straight-line method over their economic remaining useful lives. All internally-developed process costs incurred to the point when a patent application is to be filed are expensed as incurred and classified as research and development costs and reported in the consolidated statements of operations as general and administrative costs. Patent application costs and general legal costs are capitalized pending disposition of the individual patent application, and are subsequently either amortized based on the initial patent life granted, generally 15 to 20 years for domestic patents and 5 to 20 years for foreign patents, or expensed if the patent application is rejected. The costs of defending and maintaining patents are expensed as incurred. Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts. Licenses Licenses that allow us to use certain technology in the production of our products are amortized on a straight-line basis over their remaining useful life (typically 15-17 years). Long-lived assets, including licenses, property and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We assess the recoverability of our long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. We have recorded an impairment on our licenses in the amount of $49,895 and $110,000 on December 31, 2016 and 2015, respectively. As of December 31, 2016, the carrying value of our licenses are $0. Discount on convertible notes payable We allocate the proceeds received from convertible notes between convertible notes payable and warrants, if applicable. The resulting discount for warrants is amortized using the effective interest method over the life of the debt instrument. After allocating a portion of the proceeds to the warrants, the effective conversion price of the convertible note payable can be determined. If the effective conversion price is lower than the market price at the date of issuance, a beneficial conversion feature is recorded as an additional discount to the convertible note payable. The beneficial conversion feature discount is amortized using the effective interest method over the life of the debt instrument. The amortization is recorded as interest expense on the consolidated statements of operations. Fair value of financial instruments The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable and accounts payable approximate their fair values determined based on level 1 inputs in the fair value hierarchy because of the short maturity of these instruments. Due to conversion features and other terms, it is not practical to estimate the fair value of notes payable and convertible notes. Fair value measurements We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. Where reliable, reputable third-party appraisals are available, these are used to determine value or aid in determining value. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions. We do not have any assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at December 31, 2016 or 2015, nor any gains or losses reported in the consolidated statement of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the years ended December 31, 2016 and 2015. Revenue recognition We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectibility of amounts is reasonably assured. Revenues from the sale of products, including shipping and handling fees but excluding statutory taxes collected from customers, as applicable, are recognized when shipment has occurred. We sell our products directly to customers and distributors. Persuasive evidence of an arrangement is demonstrated via order and invoice, product delivery is evidenced by a bill of lading from the third-party carrier and title transfers upon shipment, the sales price to the customer is fixed upon acceptance of the order and there is no separate sales rebate, discount, or volume incentive. Allowances for product returns, primarily in connection with one distribution agreement, are provided at the time the sale is recorded. This allowance is based upon historical return rates for the Company and relevant industry patterns, which reflects anticipated returns of unopened product in its original packaging to be received over a period of 120 days following the original sale. Shipping and handling costs Amounts charged to customers for shipping products are included in revenues and the related costs are classified in cost of goods sold as incurred. In 2016 and 2015, we incurred $14,904 and $27,848, respectively, in shipping costs included in cost of goods sold. Advertising costs Costs associated with the advertising of our products are expensed as incurred. Research and development Research and development costs are charged to expense as incurred. Research and development costs consist primarily of material and testing costs for research and development as well as research and development arrangements with unrelated third party research and development institutions. These research and development arrangements usually involve one specific research and development project. We may make non-refundable advances upon signing of these arrangements. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or as the related services are performed. Management periodically evaluates whether the goods will be delivered or services will be rendered. If management does not expect the goods to be delivered or services to be rendered, the capitalized advance payment is charged to expense. Research and development expense was $37,750 and $73,394 in 2016 and 2015, respectively and are classified as general and administrative on the consolidated statement of operations. Equity instruments issued to parties other than employees for acquiring goods or services We account for all transactions in which goods or services are the consideration received for the issuance of equity instruments based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. However, where reliable, reputable third-party appraisals are available, these are used to determine value or aid in determining value. Such transactions have included both common stock or awards of warrants to purchase common stock. The fair value of each warrant award is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The assumptions used to determine the fair value of our warrants are as follows: - The expected life of warrants issued represents the period of time the warrants are expected to be outstanding. - The expected volatility is generally based on the historical volatility of comparable companies’ stock over the contractual life of the warrant. - The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the warrant. - The expected dividend yield is based on our current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the warrant. Income taxes We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our consolidated statements of income in the period that includes the enactment date. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in our consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. The tax years that are open to examination are 2013, 2014, 2015 and 2016. Net loss per common share Basic and diluted net loss per share has been computed by dividing our net loss by the weighted average number of common shares issued and outstanding. Convertible preferred stock, options and warrants to purchase our common stock as well as debt which are convertible into common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share for 2016 and 2015. The following table presents a reconciliation of basic loss per share and excluded dilutive securities: For the Years Ended 2016 2015 Numerator: Net loss allocable to common stockholders $ (1,395,782 ) $ (2,260,050 ) Denominator: Weighted-average common shares outstanding 28,136,527 24,289,381 Basic and diluted net loss per share $ (0.05 ) $ (0.09 ) Common stock warrants 21,122,633 18,495,578 Series A convertible preferred stock 9,428,150 9,565,350 Stock options 2,822,970 2,898,220 Convertible debt including interest 3,845,525 601,775 Excluded dilutive securities 37,219,278 31,560,923 Reclassifications Certain reclassifications have been made to prior period financial statements and footnotes in order to conform to the current period's presentation. Segments We have determined that we operate in one segment for financial reporting purposes. Recently issued accounting pronouncements In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory: Topic 330 (ASU 2015-11). Topic 330 currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. ASU 2015-11 requires that inventory measured using either the first-in, first-out (FIFO) or average cost method be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Adoption of ASU 2015-11 is required for fiscal reporting periods beginning after December 15, 2016, including interim reporting periods within those fiscal years. The Company does not expect adoption of ASU 2015-11 to have a material impact on its consolidated financial statements. In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (ASU-2016-09). The updated guidance simplifies and changes how companies account for certain aspects of share-based payment awards to employees, including accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification of certain items in the statement of cash flows. Adoption of ASU 2016-09 is required for fiscal reporting periods beginning after December 15, 2016, including interim reporting periods within those fiscal years with early adoption being permitted. The Company does not expect the adoption of ASU 2016-09 to have a material impact on its consolidated financial statements. In May 2014, the FASB issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for Entia in the first quarter of 2018, and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are evaluating the impact of adopting this new accounting standard on our financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This update requires organizations to recognize lease assets and lease liabilities on the balance sheet and to disclose key information about leasing arrangements. This ASU is effective for annual reporting periods beginning on or after December 15, 2018, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual period. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements.

NOTE 3 - INVENTORY

NOTE 3 - INVENTORY	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	NOTE 3 – INVENTORY Inventory consists of the following at: December 31, 2016 December 31, 2015 Raw materials $ 195,230 $ 219,074 Finished goods 25,593 27,313 220,823 246,387 Less reserve for excess and obsolete inventory (151,064 ) (151,064 ) 69,759 95,323 Less current portion (69,759 ) (40,323 ) $ - $ 55,000

NOTE 4 - PROPERTY AND EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 – PROPERTY AND EQUIPMENT Property and equipment, stated at cost, consists of the following at: December 31, 2016 December 31, 2015 Office equipment $ 31,658 $ 31,658 Production equipment 90,899 90,899 Leasehold improvements 16,328 16,328 138,885 138,885 Less: accumulated depreciation (120,600 ) (106,199 ) $ 18,285 $ 32,686 Depreciation expense was $14,401 and $18,512 for the years ended December 31, 2016 and 2015, respectively.

NOTE 5 - PATENTS AND LICENSES,

NOTE 5 - PATENTS AND LICENSES, NET	12 Months Ended
	Dec. 31, 2016
Disclosure Text Block [Abstract]
Intangible Assets Disclosure [Text Block]	NOTE 5 – PATENTS AND LICENSES, NET Our identifiable long-lived intangible assets are patents and licenses. During 2016 and 2015, management analyzed our intangibles for possible impairment. We have recorded for 2016 and 2015 an impairment in the amount of $49,895 and $110,000, respectively. We have no amortizable licenses on the financial statements at December 31, 2016. Prior to being fully impaired, the licenses were being amortized over an economic useful life of 15-17 years. The gross carrying amounts and accumulated amortization related to these intangible assets consist of the following at: December 31, 2016 December 31, 2015 Licenses and amortizable patents $ 97,244 $ 97,244 Unamortized patents 186,509 179,393 Accumulated amortization (97,244 ) (44,053 ) Patents and Licenses, net $ 186,509 $ 232,584 Amortization expense for licenses and amortizable patents were $3,296 and $13,484 for the years ended December 31, 2016 and 2015, respectively.

NOTE 6 - ACCOUNTS PAYABLE AND A

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 6 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accrued expenses (included with accounts payable) consisted of the following at: December 31, 2016 December 31, 2015 Executive compensation $ 676,450 $ 327,285 Other accruals 30,600 38,022 $ 707,050 $ 365,307 Executive compensation accrued above includes $327,285 of unpaid wages from 2014 and 2015 that have subsequently been forgiven by our Chairman. See Note 13 – Subsequent Events.

NOTE 7 - NOTES PAYABLE

NOTE 7 - NOTES PAYABLE	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 7 – NOTES PAYABLE Notes payable comprise the following at the dates indicated: December 31, 2016 December 31, 2015 Notes payable - current 5.86% unsecured, $781 due monthly $ - $ 2,687 4.15% unsecured, $3,436 due monthly - 36,374 8.95% unsecured, $314 due monthly 306 - 8.95% unsecured, $748 due monthly 710 - 10% unsecured, due August 2017 10,000 - 3.9% unsecured, $4,417 due monthly 51,203 - $ 62,219 $ 39,061 Convertible notes payable, net $59,400, 0% unsecured was due in April 2017, net of discount related to warrants, convertible into common stock at $0.10 per share. Existing note of $55,000 was converted into the new note during first quarter 2016 with $4,400 of accrued interest being added to principal. This note has been extended until April 2018 at 8% interest. In exchange for extending the note, a five-year warrant to purchase 100,000 shares of common stock at $0.10 per share was granted. $ 59,400 $ 50,000 6% unsecured, convertible into common stock at $2.00 per share, due on demand 50,000 50,000 $11,333, 8% unsecured due December 2018, net of discount related to warrant, convertible into common stock at $0.10 per share. Existing note of $10,000 was converted into the new note during first quarter 2016 with $1,333 of accrued interest being added to principal. 10,857 10,000 $11,000, 8% unsecured due October 2018, net of discount related to warrant, convertible into common stock at $0.10 per share. Existing note of $10,000 was converted into the new note during first quarter 2016 with $1,000 of accrued interest being added to principal. Remaining $208 in accrued interest was forgiven and reported as a gain on extinguishment of debt on the statement of operations. 10,538 10,000 $50,000, 8% unsecured due November 2018, net of discount related to warrant, convertible into common stock at $0.10 per share. 48,031 46,981 $15,000, 8% unsecured due November 2018, net of discount related to warrant, convertible into common stock at $0.10 per share. Existing 0% note of $15,000 exchanged into new note during first quarter 2016. 14,370 15,000 $50,000, 8% unsecured due March 2019, net of discount related to warrant, convertible into common stock at $0.10 per share. 47,725 - $25,000, 8% unsecured due March 2019, net of discount related to warrant, convertible into common stock at $0.10 per share. 23,862 - $100,000, 8% unsecured due April 2019, net of discount related to warrant, convertible into common stock at $0.10 per share. 96,250 - $50,000, 10% unsecured due August 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 47,933 - $15,000, 10% unsecured due September 2017, net of discount related to warrants, convertible into common stock at a price to be determined. 12,910 - $10,000, 10% unsecured due September 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 8,815 - $25,000, 8% unsecured due June 2019, net of discount related to warrant, convertible into common stock at $0.10 per share. 24,417 - $250,000, 10% unsecured due October 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 220,937 - $50,000, 10% unsecured due October 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 44,188 - $50,000, 10% unsecured due October 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 44,188 - $25,000, 10% unsecured due October 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 20,646 - $50,000, 10% unsecured due December 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 37,829 - $50,000, 10% unsecured due December 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 42,250 - $20,000, 10% unsecured due December 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 16,340 - Total Convertible Notes Payable 881,486 181,981 Less: Current Portion (605,436 ) (181,981 ) $ 276,050 $ - Convertible notes payable, net, related party $10,000, 10% unsecured due December 2017, net of discount related to warrant, convertible into common stock at a price to be determined. $ 8,322 $ - $25,000, 8% unsecured due May 2019, net of discount related to warrant, convertible into common stock at $0.10 per share. $ 24,028 $ - Total Convertible Notes Payable, net, related party $ 32,350 $ - Less: Current Portion (8,322 ) - $ 24,028 $ - Notes payable, related party $10,000, 10% unsecured due in August 2017 $ 10,000.00 $ - $ 10,000.00 $ - Line of Credit On March 25, 2014, we entered into an unsecured line of credit arrangement that renews annually unless terminated by either party. The line of credit is $60,000 with an interest rate of prime plus 3.00%, resulting in an interest rate of 6.5% at December 31, 2016. There are no loan covenants applicable to this line of credit and the amounts outstanding are $59,945 and $58,195 as of December 31, 2016 and 2015, respectively.

NOTE 8 - RELATED PARTY TRANSACT

NOTE 8 - RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 8 – RELATED PARTY TRANSACTIONS Investments and loans from officers or board members On February 18, 2016, our Chairman and Chief Science and Technology Officer lent us $10,000 in the form of a 10% unsecured note, the due date of which has been extended to August 2017. On May 20, 2016, our Chief Executive Officer invested $25,000 in our 8% convertible note payable (with an attached warrant), due May 2019. On December 5, 2016, our Chairman and Chief Science and Technology Officer invested $10,000 in our 10% convertible promissory note (with an attached warrant), due December 2017. Common stock issued On April 17, 2015, the board of directors authorized and granted to its executives and board or directors for the year end 2015, restricted common stock bonuses as follows: · Marvin Hausman, former CEO and director, 600,000 shares valued at $120,000 · Devin Andres, former COO, 550,000 shares valued at $110,000 · Philip Sobol, former director, 200,000 shares valued at $40,000, and · Elliott Shelton, director, 200,000 shares valued at $40,000. During December 2015, Messrs. Hausman, Sobol and Shelton surrendered their stock certificates in the amounts detailed above with the understanding that equity securities in some form would be granted in the future to replace the aforementioned grants. That replacement took place during the first quarter 2017. See Note 13 – Subsequent Events. As of third quarter 2015, Mr. Andres was no longer an officer of the company and, as of fourth quarter 2015, Mr. Sobol was no longer a director.

NOTE 9 - STOCKHOLDERS' EQUITY (

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT)	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9 – STOCKHOLDERS’ EQUITY (DEFICIT) Preferred Stock On May 26, 2011, our board of directors designated 350,000 shares of preferred stock as Series A preferred stock, $0.001 par value. The Series A preferred stock is entitled to a liquidation preference in the amount of $5 per share, votes on an as converted basis with the common stock on all matters as to which holders of common stock shall be entitled to vote, and due to an anti-dilution right, is convertible into common stock on a one-for-fifty basis. Common stock The Company is authorized to issue 150,000,000 shares of common stock at $0.001 par value. Stock incentive plan The Entia Biosciences, Inc. 2010 Stock Incentive Plan was adopted by the board of directors on September 17, 2010 and approved by the stockholders on October 21, 2010. Initially 15 million shares were reserved for issuance under the Plan. On January 1, 2012, 500,000 additional shares were automatically added to the shares reserved for issuance under the Plan, pursuant to an evergreen provision in the Plan. On February 15, 2012, pursuant to a 1:10 reverse stock split the number of shares reserved for issuance under the Plan was reduced from 15,500,000 shares to 1,550,000 shares. Between 2013 and 2015, in addition to the 150,000 shares that were automatically added, on two separate occasions shareholders approved an additional 1.5 million shares each to be added bringing the total shares reserved to 4,700,000 shares. On January 1, 2016, another 50,000 shares were automatically added to the shares reserved for issuance bringing the total to 4,750,000 shares. Generally, stock options have been granted at or below the last sale price of our common stock on the date of grant for terms ranging from four to fifteen years and vesting over five-years. The fair value of the option grants was calculated at the date of the grants using the Black-Scholes option pricing model with the following assumptions: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Price Exercise Contractual Term Intrinsic Shares Range Price (Years) Value Outstanding, December 31, 2014 2,866,470 $ 0.30 - $1.00 $ 0.48 8.96 - Exercisable, December 31, 2014 2,321,001 $ 0.38 - $1.00 $ 0.47 9.50 - Granted 50,000 $ 0.09 - $0.20 $ 0.16 5.00 - Exercised - - $ - - - Expired/Forfeited 18,250 $ 0.40 - $0.50 $ 0.49 8.73 - Outstanding, December 31, 2015 2,898,220 $ .0.09 - $1.00 $ 0.43 11.25 - Exercisable, December 31, 2015 2,661,493 $ 0.20 - $1.00 $ 0.42 11.66 - Granted - - $ - - - Exercised - - $ - - - Expired/Forfeited 75,250 $ 0.40 - $1.00 $ 0.60 - - Outstanding, December 31, 2016 2,822,970 $ 0.09 - $0.81 $ 0.42 11.42 - Exercisable, December 31, 2016 2,703,184 $ 0.09 - $0.81 $ 0.41 11.66 - The range of exercise prices for options outstanding under the 2010 Stock Incentive Plan at December 31, 2016 are as follows: Number of Exercise shares Price 20,000 $ 0.09 190,000 $ 0.20 300,000 $ 0.30 55,000 $ 0.38 1,386,670 $ 0.40 10,000 $ 0.45 576,300 $ 0.50 160,000 $ 0.60 15,000 $ 0.62 100,000 $ 0.75 10,000 $ 0.81 2,822,970 At December 31, 2016, the Company had 1,927,030 unissued shares available under the Plan. Also, at December 31, 2016, the Company had $49,363 of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted average period of 5.24 years. The Company issues new shares of common stock to satisfy exercises and vesting of awards granted. Warrants Outstanding warrants to purchase common stock are as follows: Date of Issue Number of shares Exercise Price Expiration As of December 2015 18,515,300 $ 0.001 - $2.50 04/2017 - 10/2029 January-16 237,333 $ 0.125 01/2019 April-16 100,000 $ 0.125 04/2019 May-16 25,000 $ 0.125 05/2019 June-16 25,000 $ 0.125 06/2019 August-16 50.000 $ 0.10 08/2021 September-16 100,000 $ 0.10 09/2021 October-16 1,500,000 $ 0.10 10/2021 December-16 570,000 $ 0.10 12/2021 Total as of December 31, 2016 21,122,633 We use the Black-Scholes option-pricing model to determine the fair value of warrants on the date of grant. In determining the fair value of warrants, we employed the following key assumptions: December 31, 2016 December 31, 2015 Risk-Free interest rate 0.64% - 1.47 % 0.28% - 1.72 % Expected dividend yield 0 % 0 % Volatility 125.15% - 176.62 % 166.1% - 204.66 % Expected life 3 - 5 years 3 - 7 years At December 31, 2016 and 2015, the weighted-average Black-Scholes value of warrants granted was $0.05 and $0.14, respectively.

NOTE 10 - INCOME TAXES

NOTE 10 - INCOME TAXES	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 10 – INCOME TAXES For the years ended December 31, 2016, and 2015, we incurred net operating losses and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2016, we had approximately $5,715,364 of net operating losses. The net operating loss carryforwards, if not utilized, will begin to expire in 2026. The components of our deferred tax assets/liabilities as of December 31, are as follows: 2016 2015 Deferred tax assets: Reserves and accruals $ 169,000 $ 168,000 Net operating loss carryforwards 2,233,000 1,943,000 Total deferred tax assets: 2,402,000 2,111,000 Deferred tax liabilities: Depreciation and amortization 20,000 6,000 Net deferred tax assets before valuation allowance 2,382,000 2,105,000 Less: Valuation allowance (2,382,000 ) (2,105,000 ) Net deferred tax assets $ - $ - For financial reporting purposes, we have incurred a loss in each period since inception. Based on the available objective evidence, including our history of losses, we believe it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, we provided for a full valuation allowance against our net deferred tax assets at December 31, 2016, and 2015. A reconciliation between the amount of income tax benefit determined by applying the applicable U.S. statutory income tax rate to pre-tax loss for the years ended December 31, is as follows: 2016 2015 Federal Statutory Rate $ (475,000 ) $ (768,000 ) Nondeductible expenses 198,000 241,000 Change in allowance on deferred tax assets (277,000 ) (527,000 ) $ - $ -

NOTE 11 - COMMITMENTS AND CONTI

NOTE 11 - COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 11 – COMMITMENTS AND CONTINGENCIES Leases The Company has a lease agreement with on its headquarters facilities that expires in August 2018. The lease terms include a base monthly rental rate of $3,343 per month, increasing to $3,410 in August 2016, and then $3,478 in August 2017. The Company has analyzed the requirement to straight-line the full value of the lease agreement over the life of the lease and has determined that there is no need to book a deferred rent liability as the amount is immaterial. Future minimum lease payments for all of our facilities amount to $58,298 for 2017 and $37,974 through August 2018. Rent expense for the years ended December 31, 2016 and 2015 was $56,670 and $55,464, respectively. Employment Agreements During 2015, the Company entered into employment agreements with its CEO, COO/CFO and CSO. Commencement of payment of the base salaries under these employment agreements was, and continues to be, conditional on fundraising results. Management determined that no base salary for the CEO or CSO would be accrued or paid for 2015, based primarily upon the financial needs of the Company through the end of that year. Payment of base salary commenced for the COO/CFO in December 2015. We commenced accrual for payment of base salaries commenced for the CEO and CSO on January 1, 2016. Litigation During 2016, we were involved in arbitration with a former employee who had made claims against us in connection with his Separation and Release Agreement, along with other potential allegations seeking approximately $93,000, plus punitive damages. The Company was notified on August 21, 2016 that the Company failed to prove that the employee/claimant’s actions would allow the arbitrator to reach the conclusion that such actions constituted a breach of the employee’s Separation and Release Agreement and, accordingly, the Company paid the former employee $93,074 plus accrued interest of 9% per annum, totaling $6,283 through September 30, 2016. This amount is shown in the financial statements as a loss on litigation. Although we were not party to litigation at December 31, 2016, during the first quarter 2017, we became a party to litigation with respect to a particular note payable, with a face amount of $50,000 and the accrued interest thereon. We had previously been party to litigation with respect to this note, but with a different plaintiff who dropped that lawsuit without prejudice. The Company will defend itself vigorously and reserves the right to make counter claims against the adversarial parties. Although we believe that this situation will be settled in due time, without material effect to the Company or its future operations, we can offer no assurance to that effect.

NOTE 12 - CONCENTRATIONS AND CR

NOTE 12 - CONCENTRATIONS AND CREDIT RISK	12 Months Ended
	Dec. 31, 2016
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	NOTE 12 – CONCENTRATIONS AND CREDIT RISK Customers and Credit Concentrations During 2016 and 2015 approximately 48% and 42%, respectively, of our sales were to 5 customers. Accounts receivable for the top 5 customers accounted for 62% and 57% of total accounts receivable at December 31, 2016 and 2015, respectively. Vendor Concentrations During 2016, approximately 78% of our purchases were made from 5 vendors as compared to 64% during 2015. Accounts payable for these vendors accounted for 0.16% and 0.5% of total accounts payable at December 31, 2016 and 2015, respectively.

NOTE 13 - SUBSEQUENT EVENTS

NOTE 13 - SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 13 – SUBSEQUENT EVENTS In February 2017, 600,000, 200,000 and 200,000 shares, respectively, were re-issued to our Chairman, Dr. Marvin Hausman, a director, Elliot Shelton and a former director, Philip Sobol, to replace shares previously surrendered to the Company. In February 2017, 500,000, 600,000, and 550,000 shares were issued to Hausman, Johnson and Timmins, respectively, as compensation pursuant to their 2015 employment contracts, as adjusted by the board of directors. In February 2017, 1,861,170 shares were issued to Dr. Hausman in conjunction with his forgiveness of $327,285 of unpaid wages from 2014 and 2015. A five-year warrant to purchase 100,000 shares of our restricted Common Stock, exercisable at $0.10 per share was also granted to him as consideration from the disinterested directors. The shares were valued at $18,612 and will be expensed during 2017. In February 2017, 250,000 shares were awarded to Mr. Shelton for his service as the sole outside director during 2016 and 250,000 shares each were awarded to Messrs. Hausman, Johnson and Timmins in conjunction with replacement employment contracts being drafted in order to strengthen, to the benefit of the Company and its shareholders, the non-competition clauses between these individuals and the Company and, further, to remove the "evergreen" aspects of the existing contracts, instead replacing them with a finite, fixed terms. In February 2017, we entered into an executed, definitive licensing agreement with GROH Beauty Corp, a newly-formed subsidiary of an established beauty industry company, under which we granted certain exclusive worldwide rights to manufacture and distribute our GROH beauty products. The license called for a front-end license fee, half of which is non-refundable and the other half of which is subject to a number of factors during a due diligence period, as well as royalties over a period of years, also subject to the completion of the due diligence period, until the license is paid in full and thereby becomes an exclusive perpetual license of the Licensee. The total value of the license fees and royalties to us was $1,150,000. The License called for and was accompanied by a separate executed agreement under which we will manufacture and sell our ErgoD2 compound exclusively to the licensee for its use in the cosmetic and beauty care markets. As this manufacturing agreement provided for price adjustments and is expected to run for a number of future years concurrent with the License, its positive value to us presently continues to be inestimable. Additionally, the License called for a separate agreement with Entia, through which our Chief Science and Technology Officer will provide consulting services to the licensee.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation and principles of consolidation The accompanying consolidated financial statements and related notes have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Material intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of Entia and Total Nutraceutical Solutions, a wholly-owned subsidiary, as of December 31, 2016 and 2015.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents.
Receivables, Policy [Policy Text Block]	Accounts receivable Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses based on specific identification of accounts in our existing accounts receivable. Outstanding account balances are reviewed individually for collectibility. We determine the allowance based on historical write-off experience, customer specific facts and economic conditions. Bad debt expense is included in general and administrative expenses, if any. We generally consider accounts greater than 30 days old to be past due. Account balances are charged off against allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts was $5,736 at December 31, 2016 and 2015.
Inventory, Policy [Policy Text Block]	Inventory Inventory consists of finished goods and raw materials to be used in the production of our dietary supplement products, is stated at the lower of cost or market using the average cost method. We regularly review our inventory on hand and, when necessary, record a provision for excess or obsolete inventory. The portion of inventory that is not expected to be used in production of our products for more than 12 months is a long-term asset.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment Property and equipment are recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statement of operations. Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets: Office equipment 3 years Production equipment 5 to 7 years Leasehold improvements Lesser of lease term or useful life of improvement
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents Patents, once issued or purchased, are amortized using the straight-line method over their economic remaining useful lives. All internally-developed process costs incurred to the point when a patent application is to be filed are expensed as incurred and classified as research and development costs and reported in the consolidated statements of operations as general and administrative costs. Patent application costs and general legal costs are capitalized pending disposition of the individual patent application, and are subsequently either amortized based on the initial patent life granted, generally 15 to 20 years for domestic patents and 5 to 20 years for foreign patents, or expensed if the patent application is rejected. The costs of defending and maintaining patents are expensed as incurred. Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Licenses Licenses that allow us to use certain technology in the production of our products are amortized on a straight-line basis over their remaining useful life (typically 15-17 years). Long-lived assets, including licenses, property and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We assess the recoverability of our long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. We have recorded an impairment on our licenses in the amount of $49,895 and $110,000 on December 31, 2016 and 2015, respectively. As of December 31, 2016, the carrying value of our licenses are $0.
Debt, Policy [Policy Text Block]	Discount on convertible notes payable We allocate the proceeds received from convertible notes between convertible notes payable and warrants, if applicable. The resulting discount for warrants is amortized using the effective interest method over the life of the debt instrument. After allocating a portion of the proceeds to the warrants, the effective conversion price of the convertible note payable can be determined. If the effective conversion price is lower than the market price at the date of issuance, a beneficial conversion feature is recorded as an additional discount to the convertible note payable. The beneficial conversion feature discount is amortized using the effective interest method over the life of the debt instrument. The amortization is recorded as interest expense on the consolidated statements of operations.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair value of financial instruments The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable and accounts payable approximate their fair values determined based on level 1 inputs in the fair value hierarchy because of the short maturity of these instruments. Due to conversion features and other terms, it is not practical to estimate the fair value of notes payable and convertible notes.
Fair Value Measurement, Policy [Policy Text Block]	Fair value measurements We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. Where reliable, reputable third-party appraisals are available, these are used to determine value or aid in determining value. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions. We do not have any assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at December 31, 2016 or 2015, nor any gains or losses reported in the consolidated statement of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the years ended December 31, 2016 and 2015.
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectibility of amounts is reasonably assured. Revenues from the sale of products, including shipping and handling fees but excluding statutory taxes collected from customers, as applicable, are recognized when shipment has occurred. We sell our products directly to customers and distributors. Persuasive evidence of an arrangement is demonstrated via order and invoice, product delivery is evidenced by a bill of lading from the third-party carrier and title transfers upon shipment, the sales price to the customer is fixed upon acceptance of the order and there is no separate sales rebate, discount, or volume incentive. Allowances for product returns, primarily in connection with one distribution agreement, are provided at the time the sale is recorded. This allowance is based upon historical return rates for the Company and relevant industry patterns, which reflects anticipated returns of unopened product in its original packaging to be received over a period of 120 days following the original sale.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and handling costs Amounts charged to customers for shipping products are included in revenues and the related costs are classified in cost of goods sold as incurred. In 2016 and 2015, we incurred $14,904 and $27,848, respectively, in shipping costs included in cost of goods sold.
Advertising Costs, Policy [Policy Text Block]	Advertising costs Costs associated with the advertising of our products are expensed as incurred.
Research and Development Expense, Policy [Policy Text Block]	Research and development Research and development costs are charged to expense as incurred. Research and development costs consist primarily of material and testing costs for research and development as well as research and development arrangements with unrelated third party research and development institutions. These research and development arrangements usually involve one specific research and development project. We may make non-refundable advances upon signing of these arrangements. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or as the related services are performed. Management periodically evaluates whether the goods will be delivered or services will be rendered. If management does not expect the goods to be delivered or services to be rendered, the capitalized advance payment is charged to expense. Research and development expense was $37,750 and $73,394 in 2016 and 2015, respectively and are classified as general and administrative on the consolidated statement of operations.
Stockholders' Equity, Policy [Policy Text Block]	Equity instruments issued to parties other than employees for acquiring goods or services We account for all transactions in which goods or services are the consideration received for the issuance of equity instruments based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. However, where reliable, reputable third-party appraisals are available, these are used to determine value or aid in determining value. Such transactions have included both common stock or awards of warrants to purchase common stock. The fair value of each warrant award is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The assumptions used to determine the fair value of our warrants are as follows: - The expected life of warrants issued represents the period of time the warrants are expected to be outstanding. - The expected volatility is generally based on the historical volatility of comparable companies’ stock over the contractual life of the warrant. - The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the warrant. - The expected dividend yield is based on our current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the warrant.
Income Tax, Policy [Policy Text Block]	Income taxes We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our consolidated statements of income in the period that includes the enactment date. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in our consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. The tax years that are open to examination are 2013, 2014, 2015 and 2016.
Earnings Per Share, Policy [Policy Text Block]	Net loss per common share Basic and diluted net loss per share has been computed by dividing our net loss by the weighted average number of common shares issued and outstanding. Convertible preferred stock, options and warrants to purchase our common stock as well as debt which are convertible into common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share for 2016 and 2015. The following table presents a reconciliation of basic loss per share and excluded dilutive securities: For the Years Ended 2016 2015 Numerator: Net loss allocable to common stockholders $ (1,395,782 ) $ (2,260,050 ) Denominator: Weighted-average common shares outstanding 28,136,527 24,289,381 Basic and diluted net loss per share $ (0.05 ) $ (0.09 ) Common stock warrants 21,122,633 18,495,578 Series A convertible preferred stock 9,428,150 9,565,350 Stock options 2,822,970 2,898,220 Convertible debt including interest 3,845,525 601,775 Excluded dilutive securities 37,219,278 31,560,923
Reclassification, Policy [Policy Text Block]	Reclassifications Certain reclassifications have been made to prior period financial statements and footnotes in order to conform to the current period's presentation.
Segment Reporting, Policy [Policy Text Block]	Segments We have determined that we operate in one segment for financial reporting purposes.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently issued accounting pronouncements In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory: Topic 330 (ASU 2015-11). Topic 330 currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. ASU 2015-11 requires that inventory measured using either the first-in, first-out (FIFO) or average cost method be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Adoption of ASU 2015-11 is required for fiscal reporting periods beginning after December 15, 2016, including interim reporting periods within those fiscal years. The Company does not expect adoption of ASU 2015-11 to have a material impact on its consolidated financial statements. In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (ASU-2016-09). The updated guidance simplifies and changes how companies account for certain aspects of share-based payment awards to employees, including accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification of certain items in the statement of cash flows. Adoption of ASU 2016-09 is required for fiscal reporting periods beginning after December 15, 2016, including interim reporting periods within those fiscal years with early adoption being permitted. The Company does not expect the adoption of ASU 2016-09 to have a material impact on its consolidated financial statements. In May 2014, the FASB issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for Entia in the first quarter of 2018, and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are evaluating the impact of adopting this new accounting standard on our financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This update requires organizations to recognize lease assets and lease liabilities on the balance sheet and to disclose key information about leasing arrangements. This ASU is effective for annual reporting periods beginning on or after December 15, 2018, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual period. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements.

NOTE 2 - SUMMARY OF SIGNIFICA21

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2016
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) [Line Items]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table presents a reconciliation of basic loss per share and excluded dilutive securities: For the Years Ended 2016 2015 Numerator: Net loss allocable to common stockholders $ (1,395,782 ) $ (2,260,050 ) Denominator: Weighted-average common shares outstanding 28,136,527 24,289,381 Basic and diluted net loss per share $ (0.05 ) $ (0.09 ) Common stock warrants 21,122,633 18,495,578 Series A convertible preferred stock 9,428,150 9,565,350 Stock options 2,822,970 2,898,220 Convertible debt including interest 3,845,525 601,775 Excluded dilutive securities 37,219,278 31,560,923
Estimated Useful Lives [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets: Office equipment 3 years Production equipment 5 to 7 years Leasehold improvements Lesser of lease term or useful life of improvement

NOTE 3 - INVENTORY (Tables)

NOTE 3 - INVENTORY (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following at: December 31, 2016 December 31, 2015 Raw materials $ 195,230 $ 219,074 Finished goods 25,593 27,313 220,823 246,387 Less reserve for excess and obsolete inventory (151,064 ) (151,064 ) 69,759 95,323 Less current portion (69,759 ) (40,323 ) $ - $ 55,000

NOTE 4 - PROPERTY AND EQUIPME23

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment Table [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	Property and equipment, stated at cost, consists of the following at: December 31, 2016 December 31, 2015 Office equipment $ 31,658 $ 31,658 Production equipment 90,899 90,899 Leasehold improvements 16,328 16,328 138,885 138,885 Less: accumulated depreciation (120,600 ) (106,199 ) $ 18,285 $ 32,686

NOTE 5 - PATENTS AND LICENSES24

NOTE 5 - PATENTS AND LICENSES, NET (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure Text Block [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	The gross carrying amounts and accumulated amortization related to these intangible assets consist of the following at: December 31, 2016 December 31, 2015 Licenses and amortizable patents $ 97,244 $ 97,244 Unamortized patents 186,509 179,393 Accumulated amortization (97,244 ) (44,053 ) Patents and Licenses, net $ 186,509 $ 232,584

NOTE 6 - ACCOUNTS PAYABLE AND25

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses (included with accounts payable) consisted of the following at: December 31, 2016 December 31, 2015 Executive compensation $ 676,450 $ 327,285 Other accruals 30,600 38,022 $ 707,050 $ 365,307

NOTE 7 - NOTES PAYABLE (Tables)

NOTE 7 - NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Notes payable comprise the following at the dates indicated: December 31, 2016 December 31, 2015 Notes payable - current 5.86% unsecured, $781 due monthly $ - $ 2,687 4.15% unsecured, $3,436 due monthly - 36,374 8.95% unsecured, $314 due monthly 306 - 8.95% unsecured, $748 due monthly 710 - 10% unsecured, due August 2017 10,000 - 3.9% unsecured, $4,417 due monthly 51,203 - $ 62,219 $ 39,061
Convertible Debt [Table Text Block]	Convertible notes payable, net $59,400, 0% unsecured was due in April 2017, net of discount related to warrants, convertible into common stock at $0.10 per share. Existing note of $55,000 was converted into the new note during first quarter 2016 with $4,400 of accrued interest being added to principal. This note has been extended until April 2018 at 8% interest. In exchange for extending the note, a five-year warrant to purchase 100,000 shares of common stock at $0.10 per share was granted. $ 59,400 $ 50,000 6% unsecured, convertible into common stock at $2.00 per share, due on demand 50,000 50,000 $11,333, 8% unsecured due December 2018, net of discount related to warrant, convertible into common stock at $0.10 per share. Existing note of $10,000 was converted into the new note during first quarter 2016 with $1,333 of accrued interest being added to principal. 10,857 10,000 $11,000, 8% unsecured due October 2018, net of discount related to warrant, convertible into common stock at $0.10 per share. Existing note of $10,000 was converted into the new note during first quarter 2016 with $1,000 of accrued interest being added to principal. Remaining $208 in accrued interest was forgiven and reported as a gain on extinguishment of debt on the statement of operations. 10,538 10,000 $50,000, 8% unsecured due November 2018, net of discount related to warrant, convertible into common stock at $0.10 per share. 48,031 46,981 $15,000, 8% unsecured due November 2018, net of discount related to warrant, convertible into common stock at $0.10 per share. Existing 0% note of $15,000 exchanged into new note during first quarter 2016. 14,370 15,000 $50,000, 8% unsecured due March 2019, net of discount related to warrant, convertible into common stock at $0.10 per share. 47,725 - $25,000, 8% unsecured due March 2019, net of discount related to warrant, convertible into common stock at $0.10 per share. 23,862 - $100,000, 8% unsecured due April 2019, net of discount related to warrant, convertible into common stock at $0.10 per share. 96,250 - $50,000, 10% unsecured due August 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 47,933 - $15,000, 10% unsecured due September 2017, net of discount related to warrants, convertible into common stock at a price to be determined. 12,910 - $10,000, 10% unsecured due September 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 8,815 - $25,000, 8% unsecured due June 2019, net of discount related to warrant, convertible into common stock at $0.10 per share. 24,417 - $250,000, 10% unsecured due October 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 220,937 - $50,000, 10% unsecured due October 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 44,188 - $50,000, 10% unsecured due October 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 44,188 - $25,000, 10% unsecured due October 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 20,646 - $50,000, 10% unsecured due December 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 37,829 - $50,000, 10% unsecured due December 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 42,250 - $20,000, 10% unsecured due December 2017, net of discount related to warrant, convertible into common stock at a price to be determined. 16,340 - Total Convertible Notes Payable 881,486 181,981 Less: Current Portion (605,436 ) (181,981 ) $ 276,050 $ - Convertible notes payable, net, related party $10,000, 10% unsecured due December 2017, net of discount related to warrant, convertible into common stock at a price to be determined. $ 8,322 $ - $25,000, 8% unsecured due May 2019, net of discount related to warrant, convertible into common stock at $0.10 per share. $ 24,028 $ - Total Convertible Notes Payable, net, related party $ 32,350 $ - Less: Current Portion (8,322 ) - $ 24,028 $ - Notes payable, related party $10,000, 10% unsecured due in August 2017 $ 10,000.00 $ - $ 10,000.00 $ -

NOTE 9 - STOCKHOLDERS' EQUITY27

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Tables)	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Generally, stock options have been granted at or below the last sale price of our common stock on the date of grant for terms ranging from four to fifteen years and vesting over five-years. The fair value of the option grants was calculated at the date of the grants using the Black-Scholes option pricing model with the following assumptions: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Price Exercise Contractual Term Intrinsic Shares Range Price (Years) Value Outstanding, December 31, 2014 2,866,470 $ 0.30 - $1.00 $ 0.48 8.96 - Exercisable, December 31, 2014 2,321,001 $ 0.38 - $1.00 $ 0.47 9.50 - Granted 50,000 $ 0.09 - $0.20 $ 0.16 5.00 - Exercised - - $ - - - Expired/Forfeited 18,250 $ 0.40 - $0.50 $ 0.49 8.73 - Outstanding, December 31, 2015 2,898,220 $ .0.09 - $1.00 $ 0.43 11.25 - Exercisable, December 31, 2015 2,661,493 $ 0.20 - $1.00 $ 0.42 11.66 - Granted - - $ - - - Exercised - - $ - - - Expired/Forfeited 75,250 $ 0.40 - $1.00 $ 0.60 - - Outstanding, December 31, 2016 2,822,970 $ 0.09 - $0.81 $ 0.42 11.42 - Exercisable, December 31, 2016 2,703,184 $ 0.09 - $0.81 $ 0.41 11.66 -
Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Table Text Block]	The range of exercise prices for options outstanding under the 2010 Stock Incentive Plan at December 31, 2016 are as follows: Number of Exercise shares Price 20,000 $ 0.09 190,000 $ 0.20 300,000 $ 0.30 55,000 $ 0.38 1,386,670 $ 0.40 10,000 $ 0.45 576,300 $ 0.50 160,000 $ 0.60 15,000 $ 0.62 100,000 $ 0.75 10,000 $ 0.81 2,822,970
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Outstanding warrants to purchase common stock are as follows: Date of Issue Number of shares Exercise Price Expiration As of December 2015 18,515,300 $ 0.001 - $2.50 04/2017 - 10/2029 January-16 237,333 $ 0.125 01/2019 April-16 100,000 $ 0.125 04/2019 May-16 25,000 $ 0.125 05/2019 June-16 25,000 $ 0.125 06/2019 August-16 50.000 $ 0.10 08/2021 September-16 100,000 $ 0.10 09/2021 October-16 1,500,000 $ 0.10 10/2021 December-16 570,000 $ 0.10 12/2021 Total as of December 31, 2016 21,122,633
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	In determining the fair value of warrants, we employed the following key assumptions: December 31, 2016 December 31, 2015 Risk-Free interest rate 0.64% - 1.47 % 0.28% - 1.72 % Expected dividend yield 0 % 0 % Volatility 125.15% - 176.62 % 166.1% - 204.66 % Expected life 3 - 5 years 3 - 7 years

NOTE 10 - INCOME TAXES (Tables)

NOTE 10 - INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The components of our deferred tax assets/liabilities as of December 31, are as follows: 2016 2015 Deferred tax assets: Reserves and accruals $ 169,000 $ 168,000 Net operating loss carryforwards 2,233,000 1,943,000 Total deferred tax assets: 2,402,000 2,111,000 Deferred tax liabilities: Depreciation and amortization 20,000 6,000 Net deferred tax assets before valuation allowance 2,382,000 2,105,000 Less: Valuation allowance (2,382,000 ) (2,105,000 ) Net deferred tax assets $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	A reconciliation between the amount of income tax benefit determined by applying the applicable U.S. statutory income tax rate to pre-tax loss for the years ended December 31, is as follows: 2016 2015 Federal Statutory Rate $ (475,000 ) $ (768,000 ) Nondeductible expenses 198,000 241,000 Change in allowance on deferred tax assets (277,000 ) (527,000 ) $ - $ -

NOTE 1 - BUSINESS (Details)

NOTE 1 - BUSINESS (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Disclosure Text Block [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 76,050	$ 24,133	$ 99,462

NOTE 2 - SUMMARY OF SIGNIFICA30

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Allowance for Doubtful Accounts Receivable	$ 5,736	$ 5,736
Impairment of Intangible Assets, Finite-lived	49,895	110,000
Finite-Lived License Agreements, Gross	0
Shipping, Handling and Transportation Costs	14,904	27,848
Research and Development Expense	$ 37,750	$ 73,394
Number of Operating Segments	1
Domestic Patents [Member] | Minimum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Domestic Patents [Member] | Maximum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Foreign Patents [Member] | Minimum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Foreign Patents [Member] | Maximum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Technology-Based Intangible Assets [Member] | Minimum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Technology-Based Intangible Assets [Member] | Maximum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	17 years

NOTE 2 - SUMMARY OF SIGNIFICA31

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Property, Plant and Equipment, Estimated Useful Lives	12 Months Ended
	Dec. 31, 2016
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements, useful life	Lesser of lease term or useful life of improvement
Minimum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Maximum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years

NOTE 2 - SUMMARY OF SIGNIFICA32

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted [Line Items]
Net loss allocable to common stockholders (in Dollars)	$ (1,395,782)	$ (2,260,050)
Weighted-average common shares outstanding	28,136,527	24,289,381
Basic and diluted net loss per share (in Dollars per share)	$ (0.05)	$ (0.09)
Excluded dilutive securties	37,219,278	31,560,923
Warrant [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted [Line Items]
Excluded dilutive securties	21,122,633	18,495,578
Convertble Preferred Shares [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted [Line Items]
Excluded dilutive securties	9,428,150	9,565,350
Equity Option [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted [Line Items]
Excluded dilutive securties	2,822,970	2,898,220
Convertible Debt Securities [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted [Line Items]
Excluded dilutive securties	3,845,525	601,775

NOTE 3 - INVENTORY (Details) -

NOTE 3 - INVENTORY (Details) - Schedule of Inventory - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Schedule of Inventory [Abstract]
Raw materials	$ 195,230	$ 219,074
Finished goods	25,593	27,313
	220,823	246,387
Less reserve for excess and obsolete inventory	(151,064)	(151,064)
	69,759	95,323
Less current portion	$ (69,759)	(40,323)
		$ 55,000

NOTE 4 - PROPERTY AND EQUIPME34

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation	$ 14,401	$ 18,512

NOTE 4 - PROPERTY AND EQUIPME35

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 138,885	$ 138,885
Less: accumulated depreciation	(120,600)	(106,199)
Property, plant and equipment, net	18,285	32,686
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	31,658	31,658
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	90,899	90,899
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 16,328	$ 16,328

NOTE 5 - PATENTS AND LICENSES36

NOTE 5 - PATENTS AND LICENSES, NET (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 49,895	$ 110,000
Amortization of Intangible Assets	$ 3,296	$ 13,484
Licensing Agreements [Member] | Minimum [Member]
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Licensing Agreements [Member] | Maximum [Member]
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	17 years

NOTE 5 - PATENTS AND LICENSES37

NOTE 5 - PATENTS AND LICENSES, NET (Details) - Schedule of Finite-Lived Intangible Assets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	$ (97,244)	$ (44,053)
Patents and Licenses, net	186,509	232,584
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangilble assets, gross	97,244	97,244
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangilble assets, gross	$ 186,509	$ 179,393

NOTE 6 - ACCOUNTS PAYABLE AND38

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]
Accrued Salaries, Current	$ 676,450	$ 327,285
Unpaid Executive Wages from 2014 and 2015 [Member]
NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]
Accrued Salaries, Current	$ 327,285

NOTE 6 - ACCOUNTS PAYABLE AND39

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accrued Liabilities - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Schedule of Accrued Liabilities [Abstract]
Executive compensation	$ 676,450	$ 327,285
Other accruals	30,600	38,022
	$ 707,050	$ 365,307

NOTE 7 - NOTES PAYABLE (Details

NOTE 7 - NOTES PAYABLE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Line of Credit, Current	$ 59,945	$ 58,195
Line of Credit [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 60,000
Line of Credit Facility, Interest Rate at Period End	6.50%
Prime Rate [Member] | Line of Credit [Member]
NOTE 7 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate	3.00%

NOTE 7 - NOTES PAYABLE (Detai41

NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Notes payable - current
Notes payable, current	$ 62,219	$ 39,061
Related party notes payable	10,000	0
Note Payable 1 [Member] | Loans Payable [Member]
Notes payable - current
Notes payable, current	0	2,687
Note Payable 2 [Member] | Loans Payable [Member]
Notes payable - current
Notes payable, current	0	36,374
Note Payable 3 [Member] | Loans Payable [Member]
Notes payable - current
Notes payable, current	306	0
Note Payable 4 [Member] | Loans Payable [Member]
Notes payable - current
Notes payable, current	710	0
Note Payable 6 [Member] | Loans Payable [Member]
Notes payable - current
Notes payable, current	$ 51,203	$ 0

NOTE 7 - NOTES PAYABLE (Detai42

NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) - Loans Payable [Member] - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Note Payable 1 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
%	5.86%	5.86%
Due monthly	$ 781	$ 781
Note Payable 2 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
%	4.15%	4.15%
Due monthly	$ 3,436	$ 3,436
Note Payable 3 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
%	8.95%	8.95%
Due monthly	$ 314	$ 314
Note Payable 4 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
%	8.95%
Due monthly	$ 748
Note Payable 6 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
%	3.90%
Due monthly	$ 4,417

NOTE 7 - NOTES PAYABLE (Detai43

NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt - USD ($)	Dec. 31, 2016	Dec. 31, 2015
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	$ 881,486	$ 181,981
Less: Current Portion	(605,436)	(181,981)
Non-current portion	276,050	0
Convertible Notes, Related Party	32,350	0
Notes, Related Party	10,000	0
Less: Current Portion	(8,322)	0
Convertible Notes, Related Party	24,028	0
Convertible Notes Payable [Member] | Board of Directors Chairman [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Notes, Related Party	8,322	0
Convertible Notes Payable [Member] | Chief Executive Officer [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Notes, Related Party	24,028	0
Notes Payable, Other Payables [Member] | Board of Directors Chairman [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Notes, Related Party	10,000	0
Convertible Note 1 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	59,400	50,000
Convertible Note 2 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	50,000	50,000
Convertible Note 3 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	10,857	10,000
Convertible Note 4 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	10,538	10,000
Convertible Note 5 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	48,031	46,981
Convertible Note 6 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	14,370	15,000
Convertible Note 7 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	47,725	0
Convertible Note 8 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	23,862	0
Convertible Note 9 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	96,250	0
Convertible Note 10 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	47,933	0
Convertible Note 11 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	12,910	0
Convertible Note 12 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	8,815	0
Convertible Note 13 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	24,417	0
Convertible Note 14 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	220,937	0
Convertible Note 15 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	44,188	0
Convertible Note 16 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	44,188	0
Convertible Note 17 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	20,646	0
Convertible Note 18 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	37,829	0
Convertible Note 19 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	42,250	0
Convertible Note 20 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt [Line Items]
Convertible Note Payable	$ 16,340	$ 0

NOTE 7 - NOTES PAYABLE (Detai44

NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Feb. 18, 2016
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
Due	May 2,019
Gain on extinguishment of accrued interest	$ 4,708	$ 0
Convertible Notes Payable [Member] | Board of Directors Chairman [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	10.00%
Due	December 2,017
$	$ 10,000
Convertible Notes Payable [Member] | Chief Executive Officer [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	8.00%
Convertible at	$ 0.10
$	$ 25,000
Notes Payable, Other Payables [Member] | Board of Directors Chairman [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	10.00%		10.00%
Due	August 2,017
$	$ 10,000		$ 10,000
Convertible Note 1 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	0.00%	0.00%
Due	April 2,017	April 2,017
Convertible at	$ 0.10	$ 0.10
Note	Existing note of $55,000 was converted into the new note with $4,400 of accrued interest being added to principal.
Accrued interest added to principal	$ 4,400
Convertible Note 2 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	6.00%	6.00%
Due	Due on demand	Due on demand
Convertible at	$ 2	$ 2
Convertible Note 3 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	8.00%	8.00%
Due	December 2,018	December 2,018
Note	Existing note of $10,000 was converted into the new note with $1,333 of accrued interest being added to principal.
Accrued interest added to principal	$ 1,333
$	$ 11,333	$ 10,000
Convertible Note 4 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	8.00%	8.00%
Due	October 2,018	October 2,018
Convertible at	$ 0.10	$ 0.10
Note	Existing note of $10,000 was converted into the new note with $1,000 of accrued interest being added to principal.
$	$ 11,000	$ 10,000
Gain on extinguishment of accrued interest	$ 208
Convertible Note 5 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	8.00%	8.00%
Due	November 2,018	November 2,018
Convertible at	$ 0.10	$ 0.10
$	$ 50,000	$ 50,000
Convertible Note 6 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	8.00%	8.00%
Due	November 2,018	November 2,018
Convertible at	$ 0.10	$ 0.10
Note	Existing 0% note of $15,000 exchanged into new note.
$	$ 15,000	$ 15,000
Convertible Note 7 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	8.00%
Due	March 2,019
Convertible at	$ 0.10
$	$ 50,000
Convertible Note 8 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	8.00%
Due	March 2,019
Convertible at	$ 0.10
$	$ 25,000
Convertible Note 9 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	8.00%
Due	April 2,019
Convertible at	$ 0.10
$	$ 100,000
Convertible Note 10 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	10.00%
Due	August 2,017
$	$ 50,000
Convertible	convertible into common stock at a price to be determined
Convertible Note 11 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	10.00%
Due	September 2,017
$	$ 15,000
Convertible	convertible into common stock at a price to be determined
Convertible Note 12 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	10.00%
Due	September 2,017
$	$ 10,000
Convertible	convertible into common stock at a price to be determined
Convertible Note 13 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	8.00%
Due	June 2,019
Convertible at	$ 0.10
$	$ 25,000
Convertible Note 14 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	10.00%
Due	October 2,017
$	$ 250,000
Convertible Note 15 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	10.00%
Due	October 2,017
$	$ 50,000
Convertible Note 16 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	10.00%
Due	October 2,017
$	$ 50,000
Convertible Note 17 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	10.00%
Due	October 2,017
$	$ 25,000
Convertible Note 18 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	10.00%
Due	December 2,017
$	$ 50,000
Convertible Note 19 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	10.00%
Due	December 2,017
$	$ 50,000
Convertible Note 20 [Member] | Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Convertible Debt (Parentheticals) [Line Items]
%	10.00%
Due	December 2,017
$	$ 20,000

NOTE 8 - RELATED PARTY TRANSA45

NOTE 8 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	Apr. 17, 2015	Dec. 31, 2016	Dec. 05, 2016	May 20, 2016	Feb. 18, 2016
Director [Member] | Convertible Debt [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount				$ 25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$ 0.08
Director [Member] | Issuance to Director #1 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)	200,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 40,000
Director [Member] | Issucance to Director #2 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)	200,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 40,000
Chief Executive Officer [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)	600,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 120,000
Chief Operating Officer [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)	550,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 110,000
Notes Payable, Other Payables [Member] | Board of Directors Chairman [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount		$ 10,000			$ 10,000
Debt Instrument, Interest Rate, Stated Percentage		10.00%			10.00%
Convertible Debt [Member] | Board of Directors Chairman [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount			$ 10,000
Debt Instrument, Interest Rate, Stated Percentage			10.00%

NOTE 9 - STOCKHOLDERS' EQUITY46

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - USD ($)	Feb. 15, 2012	Jan. 01, 2012	May 26, 2011	Sep. 17, 2010	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Preferred Stock, Shares Authorized					5,000,000	5,000,000
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)			$ 5
Stockholders' Equity, Reverse Stock Split	1:10
Warrants, Grants in Period, Weighted-Average Grant Date Fair Value (in Dollars per share)					$ 0.05	$ 0.14
2010 Stock Incentive Plan [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,550,000			15,000,000	4,750,000	4,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		500,000			50,000	1,500,000	1,500,000	150,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					1,927,030
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)					$ 49,363
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					5 years 87 days
Stock Issued for Services Rendered [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross					150,000,000
Stock Issued During Period, Value, Share-based Compensation, Gross (in Dollars)					$ 0.001
Series A Preferred Stock [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Preferred Stock, Shares Authorized			350,000		350,000	350,000
Preferred Stock, No Par Value (in Dollars per share)			$ 0.001
Preferred Stock, Conversion Basis			one-for-fifty
Minimum [Member] | 2010 Stock Incentive Plan [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				4 years
Maximum [Member] | 2010 Stock Incentive Plan [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				15 years

NOTE 9 - STOCKHOLDERS' EQUITY47

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity - USD ($)	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity [Line Items]
Options Outstanding, Number of Shares (in Shares)	2,866,470	2,898,220
Options Outstanding, Weighted Average Exercise Price	$ 0.48	$ 0.43
Options Outstanding, Weighted Average Remaining Contractual Term	8 years 350 days	11 years 153 days	11 years 3 months
Options Outstanding, Average Intrinsic Value (in Dollars)		$ 0	$ 0
Options Exercisable, Number of Shares (in Shares)	2,321,001	2,661,493
Options Exercisable, Weighted Average Exercise Price	$ 0.47	$ 0.42
Options Exercisable, Weighted Average Remaining Contractual Term	9 years 6 months	11 years 240 days	11 years 240 days
Options Exercisable, Average Intrinsic Value (in Dollars)		$ 0	$ 0
Granted, Number of Shares (in Shares)		0	50,000
Granted, Weighted Average Exercise Price			$ 0.16
Granted, Weighted Average Remaining Contractual Term			5 years
Options Exercised, Number of Shares (in Shares)		0	0
Expired/Forfeited, Number of Shares (in Shares)		75,250	18,250
Expired/Forfeited, Weighted Average Exercise Price		$ 0.60	$ 0.49
Expired/Forfeited, Weighted Average Remaining Contractual Term			8 years 266 days
Options Outstanding, Number of Shares (in Shares)		2,822,970	2,898,220
Options Outstanding, Weighted Average Exercise Price		$ 0.42	$ 0.43
Options Exercisable, Number of Shares (in Shares)		2,703,184	2,661,493
Options Exercisable, Weighted Average Exercise Price		$ 0.41	$ 0.42
Minimum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity [Line Items]
Options Outstanding, Exercise Price	$ 0.30	0.09
Options Exercisable, Exercise Price	0.38	0.20
Granted, Exercise Price			0.09
Expired/Forfeited, Exercise Price		0.40	0.40
Options Outstanding, Exercise Price		0.09	0.09
Options Exercisable, Exercise Price		0.09	0.20
Maximum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity [Line Items]
Options Outstanding, Exercise Price	1	1
Options Exercisable, Exercise Price	$ 1	1
Granted, Exercise Price			0.20
Expired/Forfeited, Exercise Price		1	0.50
Options Outstanding, Exercise Price		0.81	1
Options Exercisable, Exercise Price		$ 0.81	$ 1

NOTE 9 - STOCKHOLDERS' EQUITY48

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range - $ / shares	Dec. 31, 2016	Dec. 31, 2015	Dec. 30, 2014
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	2,822,970	2,898,220	2,866,470
Options Exerciable at $0.09 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	20,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.09
Options Exercisable at $0.20 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	190,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.20
Options Exercisable at $0.30 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	300,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.30
Options Exercisable at $0.38 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	55,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.38
Options Exercisable at $0.40 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	1,386,670
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.40
Options Exercisable at $0.45 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	10,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.45
Options Exercisable at $0.50 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	576,300
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.50
Options Exercisable at $0.60 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	160,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.60
Options Exercisable at $0.62 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	15,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.62
Options Exercisable at $0.75 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	100,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.75
Options Exercisable at $0.81 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Outstanding	10,000
Exercise Price of Options Outstanding (in Dollars per share)	$ 0.81

NOTE 9 - STOCKHOLDERS' EQUITY49

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Stockholders' Equity Note, Warrants - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Warrants Outstanding	21,122,633	18,515,300
Warrants Expiration		04/2017 - 10/2029
Warrants Issued January 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	237,333
Warrants Outstanding, Exercise Price	$ 0.125
Warrants Expiration	01/2019
Warrants Issued April 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	100,000
Warrants Outstanding, Exercise Price	$ 0.125
Warrants Expiration	04/2019
Warrants Issued May 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	25,000
Warrants Outstanding, Exercise Price	$ 0.125
Warrants Expiration	05/2019
Warrants Issued June 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	25,000
Warrants Outstanding, Exercise Price	$ 0.125
Warrants Expiration	06/2019
Warrants Issued August 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	50
Warrants Outstanding, Exercise Price	$ 0.10
Warrants Expiration	08/2021
Warrants Issued September 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	100,000
Warrants Outstanding, Exercise Price	$ 0.10
Warrants Expiration	09/2021
Warrants Issued October 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	1,500,000
Warrants Outstanding, Exercise Price	$ 0.10
Warrants Expiration	10/2021
Warrants Issued December 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	570,000
Warrants Outstanding, Exercise Price	$ 0.10
Warrants Expiration	12/2021
Minimum [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price		$ 0.001
Maximum [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Exercise Price		$ 2.50

NOTE 9 - STOCKHOLDERS' EQUITY50

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Fair Value Measurements, Warrants, Valuation Assumptions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-Free interest rate	0.64%	0.28%
Volatility	125.15%	166.10%
Expected life	3 years	3 years
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-Free interest rate	1.47%	1.72%
Volatility	176.62%	204.66%
Expected life	5 years	7 years

NOTE 10 - INCOME TAXES (Details

NOTE 10 - INCOME TAXES (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 5,715,364
Operating Loss Carryforwards, Expiration Date	2,026

NOTE 10 - INCOME TAXES (Detai52

NOTE 10 - INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Reserves and accruals	$ 169,000	$ 168,000
Net operating loss carryforwards	2,233,000	1,943,000
Total deferred tax assets:	2,402,000	2,111,000
Depreciation and amortization	20,000	6,000
Net deferred tax assets before valuation allowance	2,382,000	2,105,000
Less: Valuation allowance	(2,382,000)	(2,105,000)
Net deferred tax assets	$ 0	$ 0

NOTE 10 - INCOME TAXES (Detai53

NOTE 10 - INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Federal Statutory Rate	$ (475,000)	$ (768,000)
Nondeductible expenses	198,000	241,000
Change in allowance on deferred tax assets	(277,000)	(527,000)
	$ 0	$ 0

NOTE 11 - COMMITMENTS AND CON54

NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$ 58,298
Operating Leases, Future Minimum Payments, Due in Two Years	37,974
Operating Leases, Rent Expense, Net	56,670	$ 55,464
Litigation, Former Employee [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Loss Contingency, Damages Sought, Value	93,000
Loss Contingency, Damages Awarded, Value	93,074
Litigation, Note Payable [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Debt Instrument, Face Amount	50,000
Accrued Interest on Damages Awarded [Member] | Litigation, Former Employee [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Loss Contingency, Damages Awarded, Value	$ 6,283
Debt Instrument, Interest Rate, Stated Percentage	9.00%
Land and Building [Member] | Operating Lease, Monthly Rental Expense, Year 1 [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals		3,343
Land and Building [Member] | Operating Lease, Monthly Rental Expense, Year 2 [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals		3,410
Land and Building [Member] | Operating Lease, Monthly Rental Expense, Year 3 [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals		$ 3,478

NOTE 12 - CONCENTRATIONS AND 55

NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cost of Goods, Total [Member] | Five Vendors [Member] | Supplier Concentration Risk [Member]
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items]
Concentration Risk, Percentage	78.00%	64.00%
Liabilities, Total [Member] | Five Vendors [Member] | Supplier Concentration Risk [Member]
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items]
Concentration Risk, Percentage	0.16%	0.50%
Five Customers [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items]
Concentration Risk, Percentage	48.00%	42.00%
Five Customers [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items]
Concentration Risk, Percentage	62.00%	57.00%

NOTE 13 - SUBSEQUENT EVENTS (De

NOTE 13 - SUBSEQUENT EVENTS (Details) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 28, 2017	Dec. 31, 2016	Dec. 31, 2015
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Class of Warrant or Rights, Granted		21,122,633	18,515,300
Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	1,150,000
Board of Directors Chairman [Member] | Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	1,861,170
Debt Conversion, Original Debt, Amount (in Dollars)	$ 327,285
Class of Warrant or Rights, Granted	100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 0.10
Warrants, Fair Value of Warrants, Granted (in Dollars)	$ 18,612
Board of Directors Chairman [Member] | Subsequent Event [Member] | Shares Issued to Replace Previously Surrendered Shares [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	600,000
Board of Directors Chairman [Member] | Subsequent Event [Member] | Shares Issued Pursuant to 2015 Employment Contracts [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	500,000
Board of Directors Chairman [Member] | Subsequent Event [Member] | Shares Issued with Replaced Employeement Agreements [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	250,000
Director [Member] | Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	250,000
Director [Member] | Subsequent Event [Member] | Shares Issued to Replace Previously Surrendered Shares [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	200,000
Former Director [Member] | Subsequent Event [Member] | Shares Issued to Replace Previously Surrendered Shares [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	200,000
Chief Executive Officer [Member] | Subsequent Event [Member] | Shares Issued Pursuant to 2015 Employment Contracts [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	600,000
Chief Executive Officer [Member] | Subsequent Event [Member] | Shares Issued with Replaced Employeement Agreements [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	250,000
Chief Financial Officer [Member] | Subsequent Event [Member] | Shares Issued Pursuant to 2015 Employment Contracts [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	550,000
Chief Financial Officer [Member] | Subsequent Event [Member] | Shares Issued with Replaced Employeement Agreements [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	250,000